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In clinical cancer research, high throughput genomic technologies are increasingly used to identify copy
number aberrations. However, the admixture of tumor and stromal cells and the inherent karyotypic het-
erogeneity of most of the solid tumor samples make this task highly challenging. Here, we propose a
robust two-step strategy to detect copy number aberrations in such a context. A spatial mixture model
is ﬁrst used to ﬁt the preprocessed data. Then, a calling algorithm is applied to classify the genomic seg-
ments in three biologically meaningful states (copy loss, copy gain and modal copy). The results of a sim-
ulation study show the good properties of the proposed procedure with complex patterns of genomic
aberrations. The interest of the proposed procedure in clinical cancer research is then illustrated by
the analysis of real lung adenocarcinoma samples.
 2011 Elsevier Inc. All rights reserved.1. Introduction
Genomic alterations are a key feature in cancer that can modify
the function of genes and thereby affect tumor development and
progression. In recent years, high-resolution microarray technolo-
gies with or without co-hybridization has replaced conventional
metaphase CGH as the standard protocol to identify DNA copy
number aberrations across the whole genome [1].
Among the major high throughput genomic technologies that
are currently used, the last generation of Affymetrix high density
array (SNP Array 6.0) is nowadays frequently considered for oncol-
ogy research (for a few, see [2–5]). This novel chip interrogates
nearly two million genetic markers, half of which focus on copy
number variants (CNV) loci. To maximize the detection of previ-
ously reported CNV, around 202,000 probes target 5677 CNV
regions from the Toronto Database of genomic variants [6]. The
remaining probes are evenly spaced along the genome to provide
a uniform coverage.
Procedures designed to detect copy-number aberrations usually
rely on a multi-step process that works either on a set of arrays or
on a single array and involves the following steps: (i) removal of
systematic sources of variation (probe-cell normalization), (iii)
probe-set summarization and (iii) copy number state allocation
to modal, copy-loss and copy-gain state.ll rights reserved.
ingapore, 60 Biopolis Street,
(C. Dalmasso), broetp@gis.a-For the normalization step, many authors [7–10] have pointed
out that improvements can be obtained taking into account GC
content and PCR fragment length, these factors affecting ampliﬁca-
tion kinetics. For the summarization step, which transforms multi-
ple probe-cell values to a single probe-set expression value, various
modeling procedures have been proposed and implemented. They
mostly rely on a simple or complex additive [11] or multiplicative
[12] model that takes into account nuisance effects such as, in par-
ticular, allelic crosstalk effects [13,14].
After these preprocessing steps, the signal to noise ratio being
usually too low to obtain single-point copy number state alloca-
tions, various calling algorithms have been proposed to increase
the sensitivity and the speciﬁcity of the copy number detection.
They rely on break-point detection models [15–21], smoothing
[22–27], Hidden Markov chain models [28–31], spatial clustering
[32] or spatial mixture model [33].
In this latter framework, we propose a single-array strategy to
detect copy number changes from high resolution genome-wide
arrays. Since it has recently been pointed out that chromosomal
breakpoints colocalize with structural variants in cancer genome
[34], we focus on non-polymorphic probes. Moreover, considering
non-polymorphic probes avoids both the probe summarizing step
and the use of genotyping algorithms, this task being much more
difﬁcult with tumor DNA than with constitutional DNA [35]. How-
ever, it is worth noting that the proposed method relies on a gen-
eral model that can be used with different platforms and different
summary indexes (including polymorphic probes).
Our probabilistic allocation procedure is presented together
with a preprocessed step designed for data generated from
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mated parameters obtained from a spatial mixture model. This
procedure is designed to cope with various chromosomal patterns
of clinical tumor samples.
The outline of this article is the following. In Section 2, we pres-
ent the preprocessing step together with the spatial mixture model
and the allocation method. In Section 3, we present the results of a
simulation study from which the behavior of the proposed proce-
dure is investigated in situation mimicking real data. The method
is then applied to a subset of real data from a clinical series of lung
adenocarcinomas. Finally, the proposed procedure and the results
are discussed in Section 4.
2. Method
2.1. Preprocessing step
Here, we consider a single array process in which each array is
normalized independently from the others. One of the advantage is
that the normalization step has not to be done again each time a
new sample is added in the study. The HapMap data [36,37] are
used as a reference for the diploid signal. As discussed in the intro-
duction, we focus on non-polymorphic probes. However, signal
intensity measurements obtained from polymorphic probes (or a
mixture of polymorphic (SNP) and non-polymorphic (CNV) probes)
may also be considered.
Let Yki be the value corresponding to the measurement of the
CNV non-polymorphic probe i ordered along the chromosome k
(with k = 1, . . . ,K and i = 1, . . . ,nk). For polymorphic probes, Y
k
i can
be the mean of the corresponding probes. We consider, on the base
2 logarithmic scale, the following copy number measure:
Hik ¼ log2 Yki
 
 Rki
where Rki is a reference signal estimated by the empirical mean of
the log-transformed intensities obtained from a pool of HapMap
samples hybridized on SNP 6.0 chips.
Let GCki and FL
k
i be the standardized variables that measures, for
the 25 bp probe i, the GC content and the PCR fragment length. To
account for the nuisance variability induced by these two factors,
we consider the following classical additive model:
Hki ¼ lþ a1GCki þ a2 GCki
 2
þ b1FLki þ b2 FLki
 2
þ e
where l is the overall average signal, a1, a2 are the regression coef-
ﬁcients associated to the linear and quadratic GC content effects, b1,
b2 are the regression coefﬁcients associated to the linear and qua-
dratic fragment length effects, and e is the residual. Systematic
sources of variation due to the GC content and the fragment length
are removed by subtracting from each logratio Hki the estimated
predicted values bHki obtained from the classical ordinary least-
squares minimization.
To reduce the measurement variability while keeping a sufﬁ-
cient level of resolution, we average the intensities over N = 50
consecutive probes and consider the following quantity:
ZkGSj ¼
1
N
X
i2GSkj
Hki  bHki
 
where GSkj ¼ fðj 1Þ  N þ 1; . . . ; j  Ng. A higher resolution can be
obtained by choosing a smaller value of N, however, this grouping
allows to obtain a good trade-off between a sufﬁciently high gen-
ome coverage (N = 50 corresponding to a median genomic size of
148 kb for the considered technology) and a good reduction in
signal to noise ratio. In the following, we note Zkj the intensity
measurement for the genomic stretch GSkj located within thechromosome k. It is worth noting that the intersection of two differ-
ent genomic stretches is empty.
2.2. Allocation procedure
Mixture models are usually considered for two main purposes
[38]. The ﬁrst is to provide an appealing semi-parametric frame-
work in which a model can ﬁt complex distributional shapes, the
second is to provide a model-based clustering of the data. Usually,
these two goals cannot be achieved simultaneously since a good ﬁt
does not necessarily translate into a meaningful clustering of the
data. Here, we propose a two-step allocation procedure. A mixture
model is ﬁrst used to ﬁt the data. Then, a calling procedure is pro-
posed to cluster the data within biologically relevant copy states
(modal, loss and gain) using previously estimated parameters.
2.2.1. Estimation step
On a single cell level, copy number changes are discrete due to
the fact that gains and losses can only occur on a per-copy basis.
However, in real practice, a clinical tumor sample is composed of
an admixture of stromal (diploid) and tumor cells that may blur
the distinction between the intensity measurements correspond-
ing to each copy state.
For estimation purpose, we consider in this work a spatial
mixture model with a ﬁxed number of components and with an
explicit model for the correlations between neighboring probes
within a genomic segment. From the literature, several numbers
of components have been considered, ranging mostly from 3 to 5
[31,33,39,29]. Here, we heuristically choose to favor the ﬁve-
component model which provides a good trade-off between a
sufﬁcient ﬂexibility to explore various levels of genomic aberra-
tions and parsimony. Results obtained from this mixture model
are then used in the allocation step.
Let Lkj be a latent categorical variable taking the values
c = 1, . . . ,5 with probabilities wkjc , such that, L
k
j ¼ c indicates that
the genomic stretch j of the chromosome k (noted GSkj ) belongs
to the latent component c. Conditional on the latent component
membership, the quantity Zkj , which correspond to the summarized
intensities of GSkj , are considered as arising independently from a
normal distribution with mean lc and variance r2, this variance
being considered as identical for the ﬁve components. Thus, the
marginal density of Zkj can be written as follows:
f ðzkj Þ ¼
X5
c¼1
wkjcf ðjlcÞ
where the quantities wkic are the mixing proportions with
0 6 wkjc 6 1 and
P5
c¼1w
k
jc ¼ 1.
As deletions and gains occur by segments along the chromo-
some, the probability of allocating a genomic stretch to a speciﬁc
component is correlated to that of its neighbors. To account for
these dependences, we introduce a spatial structure on the weights
that is speciﬁc to each chromosome. In practice, the weightswkjc are
related by a polytomous logistic transformation to ﬁve latent
Markov random ﬁelds xc,k, (each point having two adjacent neigh-
bors) which are ﬁve independent nk-dimensional latent vectors,
each distributed according to an intrinsic Gaussian conditional
autoregression model [33].
Here, our purpose is to estimate the means and the variance of
the conditional distributions together with the posterior probabil-
ity of belonging to one of the ﬁve components for each genomic
stretch. We consider a Bayesian framework, where all unknown
quantities are given prior distributions.
For unique labeling, we impose that l1 <    < l5 and we choose
ﬂat prior for the means in the observed range of the data [a  b].
For the components variance r2, we consider an inverse gamma
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distribution for the conditional variance s2c;k is a gamma distribu-
tion C(0.01,0.01) which tends to place most of the prior mass near
zero while allowing a reasonably large coefﬁcient of variation.
Inference for parameters of interest is undertaken by sampling
from their joint posterior distributions using Monte Carlo Markov
chain (MCMC) samplers implemented in the WinBUGS software
[40]. The samples provide information on quantities of prime inter-
est, the posterior probabilities PrðLkj ¼ cjdataÞ of belonging to each
component for each genomic stretch GSkj . These posterior probabil-
ities are directly estimated, after discarding the burn-in samples, as
empirical averages of the weights from the output of the algorithm.
2.2.2. Calling step
To achieve the main objective which is to cluster the genomic
stretches into three biologically meaningful copy-number states
(copy loss, modal copy and copy gain), we consider the following
calling procedure that relies on aggregating components into
copy-number states.
We ﬁrst merge components for which the inter-group variabil-
ity exceeds the intra-group variability, such components being
considered as identical. We then deﬁne the ﬁnal three copy num-
ber states as follows. The modal copy state is composed of the
component (or group of components) Gm whose conditional expec-
tation is the closest to 0. The copy-gain state is composed of all
components with a positive shift from the Gm expectation (group
Gg) while the copy-loss state is composed of all components with
a negative shift (group Gl). It is worth noting that any of the two
copy number aberration states (loss/gain) could be empty, what
corresponds, for example, to a diploid tumor sample.
For each genomic stretch, posterior probabilities of belonging to
one of the three copy-number states is calculated as the sum of the
posterior probabilities of belonging to the mixture model compo-
nents that constitute the state. Then, the classical Bayes rule is
used to assign each genomic stretch to a state. This rule, which
allocates a genomic stretch to the copy state for which the poster-
ior probability is the greatest, gives a same weight to each
misallocation.
3. Results
3.1. Simulation study
To evaluate the performance of the proposed method, we con-
ducted a simulation study. The proposed method was compared
to our previous method [33] called CGHmix and to the frequently
used circular binary segmentation method (CBS) [15,17] which has
previously been reported as one of the more efﬁcient [41,42]. For
the CBS segmentation, we used the R package DNAcopy and all
splits that were not at least three SDs apart were removed. From
the CBS segmented data, we applied two different procedures to
make explicit calls: the one proposed by Willenbrock and Fridly-
and [42] (using the R package aCGH) and the one proposed by
Van de Wiel [43] (using the R package CGHcall). In the following,
the two methods are noted CBSWF and CGHcall, respectively. All
parameters were set to their default values. In particular, for the
merging method proposed by Willenbrock and Fridlyand [42],
the signiﬁcance thresholds for Wilcoxon test and Ansari–Bradley
test were 0.01% and 5%, respectively.
We generated data that resemble the structure of real tumor
samples extracted from a previous study on lung cancer [44]. In
practice, we simulated data that mimic three different proﬁles of
genomic aberrations with a large (proﬁle A), a medium (proﬁle
B) and a small (proﬁle C) number of alterations Fig. 1.
For each dataset, we simulated n = 15,000 values corresponding
to the preprocessed data Zkj . Conditionally on its component mem-bership, each value was sampled from a normal distribution
N(alk,r2) with k = 1, . . . ,K and a 2 [0,1]. Here, K is the total number
of components that represent levels of copy number alterations,
and a is a parameter that allows us to investigate consequences
of admixture of tumor and stromal (diploid) cells as seen in real
clinical samples.
The number of components, the number of segments and their
position along the chromosomes together with the distribution
parameters were derived from real data. The Fig. 1 illustrates the
simulation scheme. While the proﬁle B represents a pattern which
is frequently seen in clinical cancer studies, the proﬁles A and C,
which representmore contrasted patterns, are designed to evaluate
the performance of the proposed method in such challenging situa-
tions. To perform a fair evaluation of ourmethod, we simulated data
with a number K of components (2, 4 and 6) which is different from
the number of components of our model (5 components).
For each of the three proﬁles, we considered 10 admixture pro-
portion situations (a ranging from 0.1 to 1). While a = 1 mimic a
situation with the admixture proportion observed in the real data,
smaller values of a allow us to study the behavior of the proposed
procedure with more noisy data (e.g. low enrichment in tumor
cells). For each of the 30 cases (three different proﬁles with 10 dif-
ferent a values), 10 replicated datasets were generated, leading to a
total of 300 simulated datasets.
For each genomic sequence GSkj , let A
k
j be the random variable
corresponding to the allocation result, and let Skj be the simulated
state Akj ; S
k
j
 
2 fGl;Gm;Ggg2
 
. The Fig. 2 displays (i) the incorrect
classiﬁcation rate Pr Akj – S
k
j
  
, (ii) the sensitivity Pr Akj –

GmjSkj – GmÞÞ and (iii) the speciﬁcity Pr Akj ¼ GmjSkj ¼ Gm
  
of
each method as a function of a. These three criteria are estimated
by the mean over the 10 iterations of (i) the real proportions of
false allocation, (ii) the real proportion of true ampliﬁcations or
deletions, and (iii) the real proportion of true modal segments,
respectively.
Simulation results show that for aP 0.5, the proposed method
leads to the smallest global error rates (60.04) whatever the con-
sidered pattern, with the greatest sensitivity (P0.96) and the
greatest speciﬁcity (P0.95). In comparison to CBSWF, the proposed
method is a bit less speciﬁc, but more sensitive. The method CGH-
call, for which the sensitivity is very low for a < 0.8 appears to be
very conservative.
To evaluate the performance of the proposed method for the
size of the regions to be detected, we generated genomic aberra-
tions of varying sizes for the deletion on the chromosome 19p (pro-
ﬁle B), while the size of the other chromosomal aberrations over
the genome remained constant. Thus, we considered genomic
aberrations ranging from 1 to 10 points (1, 3, 5 and 10), the median
genomic size for one point being 148 kb for N = 50. Different a val-
ues were considered (0.5 and 1). The sensitivities for the different
sizes are plotted in Fig. 3. These results indicate that the proposed
method has a good sensitivity to detect small genomic aberrations
in commonly encountered tumor samples.
3.2. Lung cancer dataset
We considered real hybridized samples from a recently pub-
lished study on lung adenocarcinomas [44]. Lung cancer is a com-
mon malignancy worldwide and the leading cause of death in
developed countries. In the last decade, adenocarcinoma has be-
come the most predominant histological sub-type of lung cancer.
In this context, there is a growing effort to characterize genomic
aberrations and gene expression proﬁles of this tumor [45].
Genomic DNA was hybridized with Affymetrix Genome-Wide
Human SNP 6.0 Arrays. Raw data were obtained from the CEL ﬁles.
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CBSWF and the CGHcall method to these data.
Fig. 4 displays two different lung adenocarcinoma samples. The
right panel (Sample B) shows a highly contrasted genomic pattern
for which the detection of copy-number aberrations is broadly
similar between the proposed method and CBSWF. However, it is
worth noting that the proposed method detected a gain and a dele-
tion in the chromosome 11 Fig. 5 while CBSWF only detected the
deletion. Conﬁrmatory analyses have shown that CCND1 copy gain
was associated with overexpression at (i) mRNA level (expression
was analyzed by DNA microarrays in the whole series of lung ade-
nocarcinomas) and (ii) protein level (CCND1 immunohistochemis-
try, Clone SP4, Dako).The left panel (Sample A) displays the results for a less con-
trasted sample. While the proposed method only identiﬁed a few
localized copy gains, CBSWF detected large-scale ampliﬁcations
on many chromosomes. Looking at the simulation study results
which indicated that CBSWF was less speciﬁc than the proposed
method for near diploid samples, it would be reasonable to
hypothesize that these regions are unmodiﬁed.
For both samples, the CGHcall method led to identify a lower
number of modiﬁed regions, what is in accordance with our simu-
lation study results which showed that this method is more con-
servative than the two other.
While other methods have been proposed to uncover the differ-
ent levels of copy-number changes (e.g. [46]), our allocation rule
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(modal, copy gain, copy loss) that can be easily interpreted and
provide practical information to the clinician on the set of genomic
stretches to be explored. In order to compare the two types of ap-
proaches at the task of assigning probes to gain/modal/loss states,Chromosome
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web version of this article.)we applied the method GAP [46] to the lung adenocarcinomas
samples (the results are provided as supplementary materials –
Fig. S1). For both samples, the GAP procedure leads to more conser-
vative results than the proposed one. As an example, for Sample A,
while the GAP procedure detects no copy number modiﬁcation of
chromosome 12, the proposed procedure detects copy gains in
the area of cytogenetic band 12p12.1 that harbors the classical
KRAS oncogene, this latter being overexpressed at mRNA level
(analyzed by DNA microarrays, data not shown). It is worth noting
that KRAS ampliﬁcation, which is commonly seen in non-small cell
lung cancer (15% of the cases), has been shown to be associated
with indicators of local aggressiveness and may act synergistically
with KRAS mutations to promote tumor progression [47]. As an-
other example, in the area of cytogenetic band 5p13 that harbors
SKP2 oncogene (whose overexpression is frequently found in hu-
man cancers [48]), our procedure detects copy gains while GAP
does not. An overexpression of SKP2 is also found for this sample
(DNA microarrays, data not shown). Thus, at the task of assigning
probes to gain/modal/loss states, our procedure seems to provide
more relevant results.
Finally, to evaluate the added value of polymorphic probes to
the proposed method, we compared the results obtained using
CNV probes to the results obtained using SNP probes or a mix-
ture of both (polymorphic and non-polymorphic) probes. These
results (Fig. S2) show that for highly modiﬁed samples (suchPr
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ever, for tumor samples such as Sample A, using only CNV
probes leads to more conservative and clinically relevant results.
Indeed, it is worth noting that the mixture of sharp chromo-
somal changes (chromosome 5 and 12 and 8q) with very slight
chromosomal changes (e.g. chromosome 1p) are likely to reﬂect
the tumor heterogeneity. The sharp chromosomal changes are
likely to be harbored by a majority of tumor cells, reﬂecting a
selective advantage for tumor growth, whereas the slight
changes interest only a small component of tumor cells with less
biological and clinical relevance. Thus, in this case, a conserva-
tive method seems appropriate.4. Discussion
Admixture of tumor and stromal cells together with the inher-
ent karyotypic heterogeneity of most of the solid tumor samples
represent a real challenge for methods aiming to detect chromo-
somal abnormalities.
To identify structural genomic aberrations in cancer, we pro-
pose a model-based strategy which is applied to data from the
last generation high-throughput genomic array (Affymetrix
Genome-Wide Human SNP Array 6.0). Here, we use the informa-
tion from the CNV non-polymorphic probes which highlight
genomic regions with a higher propensity for chromosomal
breakpoints.
It is worth noting that the proposed procedure is generally
applicable to different platforms and different summary indexes.
However, the results obtained with the adenocarcinoma samples
indicate that the use of polymorphic probes does not improve
the performance. How to combine polymorphic and non-
polymorphic probes remains an interesting ﬁeld of research and
future work may lead to substantial improvements in this setting.
Although it is not the main purpose of this work, we detail the
preprocessing step. It relies on a simple linear regression model
(with quadratic effects) from which systematic sources of variabil-
ity are removed, such as those related to the GC content and the
PCR fragment length. From these transformed data, the detection
of copy number aberrations is performed using a two-step strategy
that combines a spatial mixture model and a clustering procedure.
In a previous work, we proposed a strategy based on a spatial
mixture model with three components directly linked to three bio-
logically meaningful copy states (modal, loss and gain) [33]. As
shown in the simulation study, a drawback of this approach wasthat such a one to one correspondence between components and
copy states could be unrealistic in many cases.
The pragmatic two-step procedure proposed here avoids this
drawback by allowing to deal with various patterns of tumoral
samples. The ﬁrst step relies on a ﬁve components mixture model
which is ﬂexible enough to well describe different levels of geno-
mic aberrations. The second step relies on a simple calling rule that
merges components and assigns each genomic stretch to a state
following the Bayes rule.
While methods have been proposed to uncover the different
levels of copy-number changes (e.g. [46]), our allocation rule as-
signs each genomic stretch to only three pragmatic components
(modal, copy gain, copy loss) the major component being consid-
ered as the reference. Thus, copy gains and copy losses are relative
to the general content of the cell (ploidy of the tumor cells). To take
into account the problem of aneuploidy in cancer samples, other
approaches have been considered that introduced a correction in
the preprocessing step [49]. More work would be nevertheless nec-
essary to include such approaches in our procedure.
From the simulation study, we have shown that the proposed
procedure performs well with, in most cases, a high sensitivity
and a high speciﬁcity.
In this work, we did not tackle the problem of copy-neutral LOH
identiﬁcation. This question could be addressed by extending the
proposed method to criteria calculated from the polymorphic
probes, such as the so-called mirrored B allele frequency intro-
duced by Staaf et al. [50]. More work would be nevertheless
needed.
Finally, a limitation of our work is that our simulation scheme
represents an oversimpliﬁcation of the reality and that tumor sam-
ples are likely to contain several or many tumor subpopulations
with different genomic landscape. In this context, our method se-
lects only genomic events that are expressed in the main subpop-
ulation. New models have to be designed for integrating this
tumoral heterogeneity.
In conclusion, the proposed procedure is an efﬁcient way to
identify copy number aberrations when analyzing clinical tumor
samples hybridized on high resolution arrays.Acknowledgments
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